Population and risk group uptake of H1N1 influenza vaccine in mainland France 2009-2010: results of a national vaccination campaign.

Abstract:

:A mass vaccination campaign against influenza A/H1N1 was launched in France in October 2009. Vaccination was offered free of charge to the entire population according to a pre-defined order of priority. Demographic data and data on vaccinations given were recorded in a dedicated database. We analysed vaccine uptake by age, sex and region in the overall population and in certain risk groups, including pregnant women. Overall vaccine uptake was 8% and varied by age-group and sex. Vaccine uptake in pregnant women was 22.7%. These low uptakes may reflect controversies around the vaccine and vaccination policy and have important implications for future pandemic vaccination strategies.

journal_name

Vaccine

journal_title

Vaccine

authors

Bone A,Guthmann JP,Nicolau J,Lévy-Bruhl D

doi

10.1016/j.vaccine.2010.09.096

subject

Has Abstract

pub_date

2010-11-29 00:00:00

pages

8157-61

issue

51

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(10)01438-6

journal_volume

28

pub_type

杂志文章

相关文献

VACCINE文献大全
  • Purified complexes of HIV-1 envelope glycoproteins with CD4 and CCR5(CXCR4): production, characterization and immunogenicity.

    abstract::The ability to readily elicit broadly neutralizing antibodies to HIV-1 remains elusive. We and others have hypothesized that interaction of the viral envelope glycoprotein (Env, gp120-gp41) with its receptor molecules could enhance the exposure of conserved epitopes that may facilitate the elicitation of broadly neutr...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(03)00494-8

    authors: Xiao X,Phogat S,Shu Y,Phogat A,Chow YH,Wei OL,Goldstein H,Broder CC,Dimitrov DS

    更新日期:2003-10-01 00:00:00

  • Algammulin, a new vaccine adjuvant comprising gamma inulin particles containing alum: preparation and in vitro properties.

    abstract::Crystallization of inulin with alum forms a fine (1-2 micron) suspension of electron-dense ovoids; the alum is embedded in inulin particles, which are then converted to the immune stimulant polymorphic form, gamma inulin. This very stable hybrid preparation is termed Algammulin. Preferred conditions for its preparatio...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(91)90063-c

    authors: Cooper PD,Steele EJ

    更新日期:1991-05-01 00:00:00

  • Neonatal immunity and immunisation in early age: lessons from veterinary medicine.

    abstract::The objective of this paper is to review adaptive immunity of young animals using examples from my own experience and from the literature. Trials carried out by us with a modified live and inactivated canine parvovirus vaccine in newborn puppies provide evidence of the immune capacity of these puppies. With regard to ...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/s0264-410x(98)00110-8

    authors: Chappuis G

    更新日期:1998-08-01 00:00:00

  • Antigen-specific IgA and IgG responses in calves inoculated intranasally with ovalbumin encapsulated in poly(DL-lactide-co-glycolide) microspheres.

    abstract::The immunogenicity of proteins encapsulated in poly(DL-lactide-co-glycolide) (PLG) microspheres has not been investigated to any extent in large animal models. In this study, IgG and IgA responses to ovalbumin (OVA), encapsulated in microspheres was investigated following intranasal inoculation into calves. Scanning e...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(03)00432-8

    authors: Kavanagh OV,Earley B,Murray M,Foster CJ,Adair BM

    更新日期:2003-10-01 00:00:00

  • Ten-year follow-up study of neonatal hepatitis B immunization: are booster injections indicated?

    abstract::One hundred and fourteen children, born to HBsAg-positive mothers received in the first year of life passive active prophylaxis for hepatitis B virus (HBV). They have been followed up to 10 years. A booster dose given in a cohort at the 5th year does not seem to increase protection against HBV. No difference in immuno...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(97)00028-5

    authors: Resti M,Azzari C,Mannelli F,Rossi ME,Lionetti P,Vierucci A

    更新日期:1997-08-01 00:00:00

  • Rubella seroprevalence in women in the reproductive period, Mersin, Turkey.

    abstract::The aim of this study was to determine the rubella seroprevalence in women of reproductive age. This cross-sectional study was conducted on women aged 15-49 years. Serologic studies were performed by using the ELISA method. The number of women enrolled in the study was 607, the mean age was 30.7+/-9.3 years and 13.2% ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2006.09.033

    authors: Sasmaz T,Kurt AO,Ozturk C,Bugdayci R,Oner S

    更新日期:2007-01-15 00:00:00

  • The seroepidemiology of Bordetella pertussis in Israel--Estimate of incidence of infection.

    abstract::This study was undertaken to estimate the magnitude of Bordetella pertussis infections in a highly vaccinated population in Israel in order to evaluate the relationship between clinical notification data and serology-based evidence of infection. A cross-sectional survey was conducted on a total of 1982 serum samples f...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2010.02.104

    authors: Rendi-Wagner P,Tobias J,Moerman L,Goren S,Bassal R,Green M,Cohen D

    更新日期:2010-04-26 00:00:00

  • Duration of rubella immunity induced by two-dose measles, mumps and rubella (MMR) vaccination. A 15-year follow-up in Finland.

    abstract::A national two-dose vaccination program with a combined measles, mumps and rubella (MMR-II) vaccine was introduced in Finland, in 1982, immunizing children at the ages of 14-18 months and 6 years. Antibody levels were determined from serial samples from a group of originally 350 children during 15 years. The latest sa...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(00)00139-0

    authors: Davidkin I,Peltola H,Leinikki P,Valle M

    更新日期:2000-07-15 00:00:00

  • Recombinant CP40 from Corynebacterium pseudotuberculosis confers protection in mice after challenge with a virulent strain.

    abstract:BACKGROUND:Caseous Lymphadenitis (CLA) is a contagious, infectious, chronic disease caused by Corynebacterium pseudotuberculosis, which affects mainly sheep and goats. The clinical prevalence of CLA in Brazil is 30%, resulting in decreased milk production, weight loss, and unusable meat and leather. Prophylaxis is base...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2015.12.064

    authors: Droppa-Almeida D,Vivas WL,Silva KK,Rezende AF,Simionatto S,Meyer R,Lima-Verde IB,Delagostin O,Borsuk S,Padilha FF

    更新日期:2016-02-17 00:00:00

  • Immunization costs, from evidence to policy: Findings from a nationally representative costing study and policy translation effort in Tanzania.

    abstract:INTRODUCTION:Information on the costs of routine immunization programs is needed for budgeting, planning, and domestic resource mobilization. This information is particularly important for countries such as Tanzania that are preparing to transition out of support from Gavi, the Vaccine Alliance. This study aimed to est...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2020.10.004

    authors: Vaughan K,Clarke-Deelder E,Tani K,Lyimo D,Mphuru A,Manzi F,Schütte C,Ozaltin A

    更新日期:2020-11-10 00:00:00

  • Dosing regimen of the 23-valent pneumococcal vaccination: a systematic review.

    abstract:BACKGROUND:Currently, one lifetime booster of a 23-valent pneumococcal polysaccharide vaccine (PPV23) is recommended for those at highest risk of invasive pneumococcal disease (IPD) 3-5 years after initial vaccination. Due to a lack of evidence on multiple revaccinations, recommendations on repeat revaccination do not ...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2015.01.060

    authors: Caya CA,Boikos C,Desai S,Quach C

    更新日期:2015-03-10 00:00:00

  • Technological investigations with attenuated strains of Shigella for production of live vaccines. 1. Cultivation in a fermenter of an attenuated strain S. flexneri 2a with two markers.

    abstract::A method was developed for cultivation of the strain Shigella flexneri 2a 77 with two attenuated markers. It ensures the preservation of the initial properties of the strain. The regimen for control of dissolved oxygen level was optimized. It was established that yeast extract is a necessary component of the nutritive...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(87)90099-5

    authors: Nenkov P,Bratoeva M,Vitanov T,Marinova S,Denchev V,Linde K

    更新日期:1987-09-01 00:00:00

  • Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression.

    abstract::Long-term effects of therapeutic vaccination of human immunodeficiency virus (HIV)-1-infected subjects with HIV-1 p17/p24:Ty virus-like particles (p24-VLP) on progression to AIDS, death, a CD4 cell count

    journal_title:Vaccine

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1016/s0264-410x(02)00102-0

    authors: Lindenburg CE,Stolte I,Langendam MW,Miedema F,Williams IG,Colebunders R,Weber JN,Fisher M,Coutinho RA

    更新日期:2002-05-22 00:00:00

  • Distribution of adsorbed antigen in mono-valent and combination vaccines.

    abstract::The distribution of alpha-casein, bovine serum albumin (BSA), myoglobin and recombinant protective antigen (rPA) in mono-valent and combination vaccines containing aluminum hydroxide adjuvant was studied by fluorescence microscopy and flow cytometry. Green and red fluorescent probes were conjugated to the antigens. Ad...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2003.10.040

    authors: Morefield GL,HogenEsch H,Robinson JP,Hem SL

    更新日期:2004-05-07 00:00:00

  • Phase II randomized, placebo-controlled trial of M. vaccae-derived protein (PVAC) for the treatment of psoriasis.

    abstract::The treatment effect against psoriasis of an antigen (delipidated, deglycolipidated form of M. vaccae-PVAC) was investigated. One hundred and sixty-five patients were enrolled in three arms (50 or 15 microg or placebo), each receiving a total of two intradermal injections (days 0 and 21). At week 12, a 75% decrease in...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2006.03.047

    authors: Netto EM,Takahashi D,de Fátima Paim de Oliveira M,Barbosa P,Ferraz N,Paixão A,Oyafuso LK,Bortoletto C,Matos D,Paixão M,da Silva AO,Badaro R

    更新日期:2006-06-05 00:00:00

  • Association between obesity and vulnerability and serologic response to influenza vaccination in older adults.

    abstract:BACKGROUND:Serologic response to influenza vaccination declines with age. Few other host factors are known to be associated with serologic response. Our objective was to determine whether obesity and vulnerability independently predicted serologic response to influenza vaccination. METHODS:Adults ≥ 50 years were recru...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2012.03.071

    authors: Talbot HK,Coleman LA,Crimin K,Zhu Y,Rock MT,Meece J,Shay DK,Belongia EA,Griffin MR

    更新日期:2012-06-06 00:00:00

  • Adjuvant activity of fish type I interferon shown in a virus DNA vaccination model.

    abstract::There is a need for more efficient vaccines to combat viral diseases of Atlantic salmon and other farmed fish. DNA vaccines are highly effective against salmonid rhabdoviruses, but have shown less effect against other viruses. In the present work we have studied if type I IFNs might be used as adjuvants in fish DNA va...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2015.03.093

    authors: Chang CJ,Sun B,Robertsen B

    更新日期:2015-05-15 00:00:00

  • Pregnancy and safety outcomes in women vaccinated with an AS03-adjuvanted split virion H1N1 (2009) pandemic influenza vaccine during pregnancy: a prospective cohort study.

    abstract::Infection with influenza virus during pregnancy poses a significant risk of complications for both mother and fetus. During the H1N1 2009 pandemic, pregnant women constituted one of the priority groups for vaccination in many countries, creating a need for close monitoring of the safety of the vaccine in pregnant wome...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.04.114

    authors: Tavares F,Nazareth I,Monegal JS,Kolte I,Verstraeten T,Bauchau V

    更新日期:2011-08-26 00:00:00

  • Trivalent inactivated influenza vaccine (IIV3) during pregnancy and six-month infant development.

    abstract:OBJECTIVE:Despite recommendations by professional organizations that all pregnant women receive inactivated influenza vaccine, safety concerns remain a barrier. Our objective was to assess the effect of trivalent influenza vaccines (IIV3) during pregnancy on parent report 6-month infant development. METHODS:We conduct...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2020.01.059

    authors: Avalos LA,Ferber J,Zerbo O,Naleway AL,Bulkley J,Thompson M,Cragan J,Williams J,Odouli R,Kauffman TL,Ball S,Shifflett P,Li DK

    更新日期:2020-02-28 00:00:00

  • Positive role for rApxIVN in the immune protection of pigs against infection by Actinobacillus pleuropneumoniae.

    abstract::The role of in vivo-induced ApxIV toxin of Actinobacillus pleuropneumoniae in protective immunity was evaluated in pigs by administering it alone or added to a multicomponent recombinant subunit vaccine composed of recombinant ApxI, ApxII, ApxIII toxin, and 42-kDa outer membrane protein (OMP). The pigs were immunized ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.07.065

    authors: Wang C,Wang Y,Shao M,Si W,Liu H,Chang Y,Peng W,Kong X,Liu S

    更新日期:2009-09-25 00:00:00

  • Successful DNA immunisation of rats against fasciolosis.

    abstract::The liver fluke Fasciola hepatica contributes to great economic and health losses in the cattle industry in many countries, including Poland. Unfortunately, no vaccine against fasciolosis is commercially available. We have designed a DNA vaccine and tested it in rats. Groups of male or female rats received one intramu...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(00)00095-5

    authors: Kofta W,Mieszczanek J,Płucienniczak G,Wedrychowicz H

    更新日期:2000-07-01 00:00:00

  • Influenza in the Asia-Pacific region: Findings and recommendations from the Global Influenza Initiative.

    abstract::The fourth roundtable meeting of the Global Influenza Initiative (GII) was held in Hong Kong, China, in July 2015. An objective of this meeting was to gain a broader understanding of the epidemiology, surveillance, vaccination policies and programs, and obstacles to vaccination of influenza in the Asia-Pacific region ...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2016.12.064

    authors: Cowling BJ,Caini S,Chotpitayasunondh T,Djauzi S,Gatchalian SR,Huang QS,Koul PA,Lee PI,Muttalif AR,Plotkin S,Global Influenza Initiative.

    更新日期:2017-02-07 00:00:00

  • Changes in the seroepidemiology of hepatitis B infection in Catalonia 1989-1996.

    abstract::The objective of this study was to investigate the prevalence of hepatitis B markers in a representative sample of 2142 subjects in Catalonia, Spain, and to compare it with previous studies. Multiple logistical regression analysis was carried out to determine variables associated with the markers studied. The prevalen...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(00)00028-1

    authors: Domínguez A,Bruguera M,Vidal J,Plans P,Salleras L

    更新日期:2000-05-08 00:00:00

  • Mucosal immunization against hepatitis A: antibody responses are enhanced by co-administration of synthetic oligodeoxynucleotides and a novel cationic lipid.

    abstract::Hepatitis A caused by hepatitis A virus (HAV) transmitted by the fecal-oral route, results in considerable morbidity and economic loss. Mucosal immunization can be more effective than conventional injection at inducing both local and systemic immunity to HAV. Here we show that co-administration of killed HAV with synt...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2006.04.015

    authors: Mitchell LA,Joseph A,Kedar E,Barenholz Y,Galun E

    更新日期:2006-06-19 00:00:00

  • Capture EIA for determination of IgE to diphtheria and tetanus toxins in comparison to RIA.

    abstract::A capture IgE assay in EIA with diphtheria toxin and tetanus toxoid as model systems was developed and evaluated in relation to RIA in a DT booster study. The EIA and the RIA gave very similar results, although the EIA determined IgE over a wider range of concentrations, without interference by other subclasses. The c...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(97)00274-0

    authors: Wahren E,Bengtsson C,Björkstén B,Mark A,Granström M

    更新日期:1998-05-01 00:00:00

  • Evaluation of Japanese encephalitis virus E and NS1 proteins immunogenicity using a recombinant Newcastle disease virus in mice.

    abstract::Japanese encephalitis (JE) is the most important cause of acute encephalitis syndrome (AES). Japanese encephalitis virus (JEV), the prototype member of the JE serocomplex, belongs to the genus Flavivirus. The immunogenic proteins envelope (E) and non-structural protein 1 (NS1) of JEV are widely explored for the develo...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2019.11.088

    authors: Nath B,Vandna,Saini HM,Prasad M,Kumar S

    更新日期:2020-02-11 00:00:00

  • Comparison of hemagglutination inhibition and microbead array assays for the measurement of influenza antibody levels in HIV-infected adults.

    abstract:INTRODUCTION:Determining vaccine responsiveness is challenging in immune compromised individuals. The microbead array (MBA) assay is a rapid, inexpensive test for evaluating influenza vaccine immunogenicity. MBA performance was compared to hemagglutination inhibition assay (HAI) utilizing HIV seropositive vaccine recip...

    journal_title:Vaccine

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.vaccine.2016.05.020

    authors: Thorne A,Chowdhury F,Singer J,Keynan Y,Fowke KR,Cooper C,CIHR Canadian HIV Trials Network (CTN) Influenza Vaccine Research Group.

    更新日期:2016-06-30 00:00:00

  • Intranasal but not subcutaneous vaccination with LaAg allows rapid expansion of protective immunity against cutaneous leishmaniasis.

    abstract::Mucosal but not parenteral vaccination with whole Leishmania amazonensis promastigotes antigens (LaAg) is known to increase host resistance to infection by an as yet unknown immune mechanism. Since early immune responses are critical for infection establishment, in the present study the differential responses elicited...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2018.03.020

    authors: Pereira Silva Bezerra I,Amaral Abib M,Rossi-Bergmann B

    更新日期:2018-04-25 00:00:00

  • Systemic immunization with CCL27/CTACK modulates immune responses at mucosal sites in mice and macaques.

    abstract::Plasmid DNA is a promising vaccine platform that has been shown to be safe and able to be administered repeatedly without vector interference. Enhancing the potency of DNA vaccination through co-delivery of molecular adjuvants is one strategy currently under investigation. Here we describe the use of the novel chemoki...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.10.095

    authors: Kraynyak KA,Kutzler MA,Cisper NJ,Khan AS,Draghia-Akli R,Sardesal NY,Lewis MG,Yan J,Weiner DB

    更新日期:2010-02-23 00:00:00

  • A Rift Valley fever vaccine trial: 2. Serological response to booster doses with a comparison of intradermal versus subcutaneous injection.

    abstract::A booster dose of a formalin-inactivated, cell culture-propagated Rift Valley fever vaccine (TSI-GSD-200) was administered without significant reactogenicity to 60 volunteers 18 months after they received a three dose primary series. Blood was drawn for serological testing prior to boosting and 10, 49, and 180 days th...

    journal_title:Vaccine

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/0264-410x(85)90060-x

    authors: Kark JD,Aynor Y,Peters CJ

    更新日期:1985-06-01 00:00:00